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Here we examined the addition of intensity-modulated total marrow irradiation (TMI) delivered using a
linear accelerator to a myeloablative chemotherapy conditioning regimen before allogeneic hematopoietic
stem cell transplantation (HSCT). In this phase I study, we enrolled 14 patients with high-risk hematologic
malignancies who received escalating doses of TMI at 3 Gy (n ¼ 3), 6 Gy (n ¼ 3), 9 Gy (n ¼ 6), and 12 Gy
(n ¼ 2) in combination with intravenous (i.v.) ﬂudarabine 160 mg/m2 and targeted busulfan (area under the
curve, 4800 mM*minute). Peripheral blood mobilized stem cells were obtained from HLA-matched related
(n ¼ 9) or unrelated (n ¼ 4) or 1 antigen-mismatched unrelated (n ¼ 1) donors. All patients rapidly engrafted
and recovered their immune cells. Overall, Bearman extrahematologic toxicity were limited to grades 1 or 2,
with oral mucositis grade 1 in 64% and grade 2 in 36% of the patients. With a median follow-up of 1126 days
(range, 362 to 1469) for living patients, the overall survival was 50% and relapse-free survival was 43%. Of 7
deaths, 3 were due to relapse and 4 to transplantation-related complications. We conclude that 9 Gy TMI can
be combined with myeloablative chemotherapy in the design of new preparative regimens for HSCT. This
study was registered at clinicaltrials.gov as NCT00988013.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
The survival of patients with hematologic malignancies at
high risk of relapse is poor with standard chemotherapy
[1-4]. Allogeneic hematopoietic stem cell transplant (HSCT)
is a potentially curative treatment for some of these patients.
However, relapse still remains the major reason for
failure of HSCT [5-7]. Previous studies suggest that post-
transplantation relapse may be associated with chemo-
therapy resistance [8], a lack of graft-versus-tumor effect [9],
or the failure of conditioning to effectively eradicate minimaledgments on page 2040.
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ty for Blood and Marrow Transplantation.residual disease [10]. Attempts to increase the intensity
of the conditioning regimen have resulted in lower rates
of relapse, but at the same time, they have increased
transplantation-related toxicity and mortality [11-14].
In the past, conditioning regimens for high-risk leukemia
patients often included total body irradiation (TBI) [15-17].
With conventional TBI, radiation is delivered with beams of
uniform intensity and the body receives a heterogeneous
dose distribution because of differences in body thickness,
contours, and tissue densities. This may result in the delivery
of doses to the tumor that are lower than expected, but it can
also lead to higher than desired doses being delivered to
normal organs such as the heart, liver, kidney, and the lungs.
In fact, the high morbidity of full-dose TBI has limited the
success of standard regimens with TBI at 10 Gy or 12 Gy,
especially in adult patients [12,13,16]. Intensity-modulated
Table 1




Female 7 of 14
Male 7 of 14
Diagnosis
AML 9 of 14
AML in CR1 with high-risk features 5
AML in CR2 2
AML not in remission 2
ALL 2 of 14
ALL in CR1 with high-risk features 1
ALL not in remission 1
MM with progression after autologous transplantation 2 of 14
CML-AP resistant to TKI 1 of 14
Donor type
Matched related 9 of 14
Matched unrelated 4 of 14
One antigen mismatch unrelated 1 of 14
CD34þ cell dose/kg, mean 8.3  106
CR1 indicates ﬁrst complete remission; CR2, second complete remission;
ALL, acute lymphoid leukemia; MM, multiple myeloma; CML-AP, chronic
myeloid leukemia in accelerated phase; TKI, tyrosine kinase inhibitor.
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delivery commonly used in the treatment of solid tumors
that allows the prescribed dose to be conformed to the target
while sparing adjacent normal organs [18]. An IMRT
approach to irradiate bone marrow selectively while sparing
other organs (total marrow irradiation, TMI) has been pre-
viously described in clinical trials using helical tomotherapy
[19-25], whereas we have previously reported preclinical
studies on the feasibility of performing linear accel-
eratorebased intensity-modulated TMI [26-29].
Conditioning withmyeloablative doses of ﬂudarabine and
i.v. busulfan (FluBu) is commonly used in allogeneic HSCT
because of its limited toxicity. However, the results with its
use in high-risk patients remain unsatisfactory because of
the high rate of relapse [30-34]. As previous studies have
suggested that the addition of radiation to myeloablative
chemotherapy may reduce the chance of relapse [35,36], we
hypothesized that we could utilize TMI to replace TBI in
conditioning regimens containing myeloablative chemo-
therapy, thereby allowing us to effectively target the bone
marrow with higher doses of radiation without increasing
systemic toxicity. In this phase I study, we combined a
sequential FluBu regimen with escalating doses of TMI with
the primary objective of assessing the hematologic and
extrahematologic toxicity of this regimen in patients with
high-risk hematologic malignancies undergoing allogeneic
HSCT. The results shown here will allow us to design new




Patients ages 18 to 65 years old with a hematologic malignancy at high
risk of relapse because of standard cytogenetic and/or molecular charac-
teristics or because of relapse or resistance to standard therapies were
enrolled in a prospective phase I trial of allogeneic myeloablative HSCT with
TMI. The study was a conventional “3 þ 3” design utilizing escalating doses
of TMI, with the primary endpoint of ﬁnding themaximum tolerated dose of
TMI that can be added to sequential FluBu. Secondary endpoints included
the evaluation of engraftment, toxicity, overall survival, disease-related
outcomes, and immune reconstitution. The University of Illinois institu-
tional review board approved the study and informed consent was obtained
from all patients. Criteria for the enrollment of patients in the study were
according to standard eligibility criteria for myeloablative HSCT. Brieﬂy,
patients had a Karnofsky score > 70, normal kidney and liver function, left
ventricular ejection fraction > 50%, and diffusing capacity of the lung for
carbon monoxide >50% predicted.
Patients
The characteristics of the 14 patients enrolled in the study are shown
in Table 1. Median age was 52 years (range, 20 to 65), with 7 male and 7
female patients. Nine patients had acute myeloid leukemia (AML) at high
risk because of resistance or relapse after induction chemotherapy
(n ¼ 5), secondary AML (n ¼ 3) including 1 with Fms-like tyrosine kinase
3 internal tandem duplication (FLT3 ITD) mutation, and AML with a
complex karyotype (n ¼ 1). The remainder of patients had myeloma re-
lapsing after autologous transplantation (n ¼ 2), acute lymphoblastic
leukemia (n ¼ 2, 1 Philadelphia chromosome positive and 1 > 50 years of
age), and a single patient had chronic myeloid leukemia in accelerated
phase that was resistant to previous therapy with tyrosine kinase
inhibitors.
Conditioning Regimen
All patients received a sequential FluBu regimen as previously described
[37]. Brieﬂy, patients received ﬂudarabine 40 mg/m2 on days 8 to 5.
Thirteen patients received busulfan targeting an average daily systemic
exposure of 4800 mM*minute given on days4 to1. Dosing was based on a
pretransplantation test dose of .8 mg/kg performed at least 1 week before
starting conditioning [37]. Mean area under the curve for the test dose
was 1207  180 mM/minute. Actual mean daily exposure was
4806  12.7 mM*minute. A single patient received weight-based dosing of
busulfan (12.8 mg/kg total), as was permitted by the protocol if a test dosewas not possible. In addition, patients received TMI in 1 of 4 cohorts: cohort
1, 3 Gy; cohort 2, 6 Gy; cohort 3, 9 Gy; and cohort 4, 12 Gy. TMI was initially
given on day 5 (cohort 1). With increasing doses, radiation was added to
days 6, then 7, and ﬁnally 8. A schema of the conditioning regimen is
shown in Figure 1.
Total Marrow Irradiation
The feasibility and logistics of delivery of linear acceleratorebased TMI
have been previously described [26,28,29]. Brieﬂy, treatment plans were
performed using the Eclipse treatment planning system (Varian Medical
Systems, Palo Alto, CA). Because of the width and length limitations on
linear acceleratorebased treatments, 3 subplans were devised (head, chest,
and pelvis). Patients were immobilized using a customized body cradle.
Using computed tomography images, skeletal bone were deﬁned and
contoured as the planning target volume (PTV) including the cranium,
mandible, sternum, ribs, complete vertebral body, pelvis, femoral head, and
upper half of the femur. A 3 mmmargin is then added to PTV to account for
possible setup errors. Organs at risk included the lenses, whole brain,
lungs, liver, kidneys, heart, small bowel, and oral cavity. Radiation therapy
was delivered twice a day in 1.5 Gy fraction sizes, approximately 8 hours
apart.
Donors
All donors received granulocyte colonyestimulating factor at 10 to
12 mg/kg subcutaneous daily for 5 days before peripheral blood stem cell
collection. Patients and donors were matched at HLA-A, B, C, DR, and DQ by
low-resolution (related) or high-resolution (unrelated) molecular typing.
Peripheral blood stem cells were obtained from HLA-matched related
(n ¼ 9), matched unrelated (n ¼ 4), or 1 antigen mismatched unrelated
(n ¼ 1) donors. Mean CD34þ cell dose per kilogram was 8.3  106.
Graft-Versus-Host Disease
All patients received graft-versus-host disease (GVHD) prophylaxis with
methotrexate and tacrolimus. Methotrexate dosing was 10 mg/m2 on day 1
and 8 mg/m2 on days 3, 6, and 11. Tacrolimus was started on day 2 and
continued until day 180 after transplantation, at which time it could be
tapered in the absence of GVHD. In addition, patients receiving grafts from
unrelated donors received rabbit antithymocyte globulin (Thymoglobulin,
Genentech, Cambridge, MA) .5 mg/kg i.v. on day3 and 2 mg/kg on days2
and1. Acute and chronic GHVDwere graded according to standard criteria
[38,39].
Supportive Care
All patients received standard institutional prophylaxis with levo-
ﬂoxacin during neutropenia and ﬂuconazole, acyclovir, and inhaled pent-
amidine or trimethoprim/sulfamethoxazole until day 180. Routine
monitoring for cytomegalovirus viremia with preemptive treatment was
performed. Prophylactic single donor platelet transfusions were given for
platelet counts below 10  109/L.
Figure 1. Schema of study treatment. All patients enrolled received ﬂudarabine/targeted i.v. busulfan and GVHD prophylaxis with methotrexate and tacrolimus. In
addition, patients received escalating doses of total marrow irradiation depending upon which cohort patients were assigned to. ATG indicates antithymocyte
globulin; PBSC, peripheral blood stem cell.
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Engraftment and toxicity were monitored according to the Bearman
scale [40]. Dose-limiting toxicity was deﬁned as any grade 3 or 4 toxicity
attributed to study treatment up until day 30. Neutrophil engraftment was
deﬁned as an absolute neutrophil count >.5  109/L for 3 consecutive
days. Platelet engraftment was deﬁned as >20  109/L without transfusion
for 7 days. Peripheral blood chimerism was monitored in blood mono-
nuclear cells on day 30, 60, 90, 180, and 365 per our standard institutional
protocol.
Flow Cytometry
Complete blood counts and additional heparinized blood samples were
drawn before transplantation and on days 30, 90, and 180 after HSCT. Pro-
cessing of blood was as previously described [41]. The following FITC-, PE-,
or peridin chlorophyll proteineconjugated mAbs were used: CD3, CD4, CD8,
CD14, CD86, CD19, CD56, BDCA-1, and BDCA-2. Appropriate amounts of
mAbs were added to 100 mL of whole blood followed by incubation for
15 minutes at room temperature. Appropriate isotype controls were also
used. Red cells were lysed and the remaining stained cells were washed
twice in phosphate-buffered saline. Sample acquisition and analysis was
performed within 2 hours on a FACSCalibur (Becton Dickinson, San Jose, CA).
Absolute counts for each cellular fraction were calculated as the product of
the absolute white blood cell count.
Study Endpoints and Statistical Analysis
Cumulative incidence and survival were analyzed using Kaplan-Meier
statistics. Comparison of means was done by ANOVA. All analyses were
performed using GraphPad Prism v4 (GraphPad, San Diego, CA).
RESULTS
Dosimetry to Bone Marrow and Normal Organs
The overall aim of this study was to test the feasibility
and safety of adding linear acceleratorebased TMI to
myeloablative conditioning. All enrolled patients received
the full course of TMI treatment as scheduled. Overall
target coverage was comparable to IMRT treatments at
other sites with 95% of the bone marrow PTV receiving 99%
of the prescribed dose for all 14 patients. An example of
TMI dose distribution and a 3D depiction of the bone
marrow PTV are shown in Figure 2A-C. Dose to organs at
risk ranged from 31% to 85% of the prescribed dose. Spe-
ciﬁcally, the lungs received a median of 68% of the pre-
scribed dose (range, 58% to 80%). Figure 2D shows the
actual dose delivered to major organs at risk in each cohort
compared with the prescription radiation dose to the bone
marrow.Engraftment
A major safety concern addressed in this study was
whether the combination of irradiation with myeloablative
sequential FluBu would affect the ability of donor stem cells
to repopulate the bone marrow. All patients in each of the 4
groups engrafted promptly with an overall median time to
neutrophils >.5  109/L of 15 days (range, 10 to 20) and
platelets >20  109/L of 15.5 days (range, 8 to 9). There was
no statistical difference in time to engraftment between each
cohort. Furthermore, there was no difference in cumulative
engraftment when low-dose cohorts 1 and 2 were compared
to high-dose cohorts 3 and 4 (data not shown). All patients
showed full donor chimerism at day þ30 and there were no
instances of secondary graft failure.Toxicity
The primary endpoint of this study was to determine
the maximum tolerated dose of TMI administered in
combination with myeloablative sequential FluBu. For this
purpose, escalating doses of TMI were administered to the
4 patient cohorts and extrahematologic toxicity was
monitored according to the Bearman scale until day 30. All
patients survived beyond 30 days. No grade 3 or 4 toxicities
were detected during this time period in any of the pa-
tients. All patients experienced oral mucosal toxicity,
which was a maximum of grade 2 in 5 patients (36%). Of
these, 2 had received 12 Gy and 3 received 6 Gy. In addi-
tion, 3 patients experienced grade 1 gut toxicity, 1 patient
grade 2 cardiac toxicity, and 1 patient grade 2 renal
toxicity. A speciﬁc dose-limiting toxicity could not be
clearly deﬁned in the study. The 9 Gy cohort was expanded
to 6 patients after the death of the ﬁrst 2 patients in this
group from liver failure on day 262 in 1 case and from
acute GVHD and infection on day 71 in the second. Of the
other 4 patients in this cohort, 1 died of late complications
because of bronchiolitis obliterans. Both patients in the
12 Gy cohort died. The ﬁrst died of pneumonia on day 86
with negative blood and bronchoalveolar lavage cultures
and no viral detection by PCR assays. The second patient
died in leukemic relapse due to gastrointestinal hemor-
rhage at day 85. A biopsy of the stomach was consistent
Figure 2. (A,B) show Representative isodose distribution for a patient receiving TMI. (C) 3D planning target volume for a representative patient. (D) Median TMI dose
delivered to organs at risk for patients in each cohort. Line on each graph illustrates the prescribed TMI dose.
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infection. Although these events occurred beyond day 30,
the cases were reviewed by the protocol data safety
monitoring board. As it could not be excluded that TMI had
partially contributed to the lung or intestinal toxicity in
these 2 patients, the study was closed.
Clinical Results
All enrolled patients had a poor prognosis because of
hematologic malignancies at a high risk of relapse (Table 2).
With a median follow-up of 1126 days (range, 362 to 1469)for living patients, overall survival was 50% and relapse-free
survival was 43% (Figure 3), with 1 patient affected by
myeloma who remains alive with disease more than 4 years
after transplantation. Of 7 deaths, 6 occurred in patients who
received 9 or 12 Gy of TMI and were related to relapse (n¼ 3)
or transplantation-related complications (n ¼ 4: 1 liver fail-
ure at day 262, 2 infections at days 71 and 86,1 lung GVHD at
day 709). The overall transplantation-related mortality
(TRM) was 29%. Acute GVHD grade II to IV occurred in 43% of
the patients and was grade III to IV in only 1 patient (7%).
Median overall survival is 27 months and the median
Table 2
Outcome of Patients Enrolled in the Four Cohorts of the Study
Age/Gender Diagnosis Disease Status
at Transplantation
High-Risk Feature Donor TMI Dose Toxicity
(Bearman Grade)
Follow-up, d, and Status
63/M MM PD Relapse after auto
with cytogen. abn.
Related 3 Mucosal (1) 1469, alive with disease
52/F AML CR1 Resistant to initial induction Related 3 Mucosal (1) 1245, alive in remission
63/F AML PD Cytogenetic relapse Related 3 Mucosal (1) 808, died of relapse
52/M AML CR1 Secondary AML Related 6 Mucosal (2) 1126, alive in remission
38/M MM VGPR Relapse after auto Related 6 Mucosal (2) 1063, alive in remission
Cardiac (2)
38/F AML CR2 Prior relapse Unrelated 6 Mucosal (2) 1132, alive in remission
Gut (1)
65/M AML PD Secondary AML Unrelated 9 Mucosal (1) 262, died of liver failure
Gut (1)
61/F AML CR2 Prior relapse Unrelated 9 Mucosal (1) 71, died of aGVHD/infection
39/F AML CR1 FLT3þ, secondary AML Unrelated 9 Mucosal (1) 709, died of bronchiolitis
52/M B-ALL CR1 Age >50 Related 9 Mucosal (1) 183, died of relapse
31/M CML Hematologic response CML-AP resistant to TKI Related 9 Mucosal (1) 488, alive in remission
20/M AML CR1 Complex karyotype Unrelated 9 Mucosal (1) 362, alive in remission
62/M AML CR1 Failed response to initial
induction
Related 12 Mucosal (2) 86, died of pneumonia
53/F ALL PD (molecular relapse) t(9;22) Related 12 Mucosal (2) 85, died of GI hemorrhage
after relapseGut (1)
Renal (2)
M indicates male; PD, progressive disease; ctyogen. abn., cytogenetic abnormality; F, female; VGPR, very good partial response; auto, autologous cell trans-
plantation; B-ALL, B cell acute lymphoid leukemia; GI, gastrointestinal.
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6.5 to 18).
Immune Reconstitution
To test whether the addition of TMI to sequential FluBu
would adversely affect immune reconstitution, we compared
the absolute number of immune cell subsets detected in
peripheral blood before and 30, 60, or 180 days after trans-
plantation in the patients in cohorts 1 to 3 (Figure 4). The
results of patients in cohort 4 are not shown because of short
follow-up. No statistically signiﬁcant differences were
observed in CD3, CD4, or CD8 levels between the 3 groups at
any time point tested. In all cohorts, there was an expected
slight decrease in CD4þ cells after transplantation, with re-
covery by day 180. A decrease below 200 cells/mL was only
seen in the 9 Gy cohort at 60 days after transplantation. As
expected, there was a progressive slow increase in CD19
levels towards day 180. We noted a rapid early increase in
natural killer cell numbers across all cohorts. Overall, the
combination of sequential FluBu and escalating doses of TMIFigure 3. Kaplan-Meier curve to show overall and relapse-free survival for all
patients.up to 9 Gy did not impair patients’ immune reconstitution
after HSCT.DISCUSSION
Here we report the ﬁrst use of TMI in addition to mye-
loablative conditioning before allogeneic HSCT. By using a
linear acceleratorebased platform, the maximum tolerated
dose of TMI that could be delivered in combination with
myeloablative doses of ﬂudarabine and i.v. busulfan is 9 Gy.
The rationale for using increased doseeintensity condi-
tioning regimens for high-risk patients is based on the high
relapse rate that occurs with standard myeloablative HSCT.
Previous studies have demonstrated that the intensity of
the conditioning regimen affects the risk of relapse. In the
report from Clift et al., patients with AML in ﬁrst complete
remission undergoing HSCT conditioned with fractionated
TBI at 15.75 Gy experienced a lower relapse rate compared
with those treated with TBI at 12 Gy [12]. The same group
also reported similar ﬁndings in transplantations per-
formed in chronic myeloid leukemia patients [13]. However,
because of the higher rates of TRM for patients treated with
higher doses of TBI, there was no difference in long-term
disease-free survival between patients treated at 15.75 Gy
or 12 Gy in either of these studies. Bacigalupo et al. found,
in a group of 150 patients with AML conditioned with TBI,
that patients who received a dose less than 9.9 Gy had a
higher risk of relapse compared with those who received a
higher dose (43% versus 19%) [42]. Similar ﬁndings have
been reported in studies of reduced-intensity conditioning
regimens utilizing i.v. busulfan at 6.4 mg/kg compared with
3.2 mg/kg [10].
Strategies to improve the results of HSCT in high-risk
patients through alterations in the conditioning regimen
include combining chemotherapy with irradiation to over-
come failures that may result from chemotherapy resistance.
Russell et al. [35,36] demonstrated that in patients with AML,
the addition of TBI 4 Gy to a myeloablative FluBu regimen
decreased the relapse rate from 79% to 33%. The risk of
Figure 4. Immune reconstitution studies showing numbers of circulating cells in the peripheral blood. Time points for sampling were before transplantation, and 30,
60, and 180 days after transplantation for patients in cohorts 1, 2, and 3. Cohort 4 is not shown because of lack of follow-up. No signiﬁcant difference was found in any
cell types between any doses. Values shown are mean  standard error.
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approach limits the dose of radiation that can be delivered.
The development of IMRT techniques in the treatment of
patients with solid tumors has allowed effective targeting of
the tumor area while sparing the surrounding tissues.
Therefore, we addressed the hypothesis that TMI could
replace TBI in conditioning regimens with myeloablative
chemotherapy with the advantage of targeting the bone
marrow with higher doses of irradiation without increasing
the overall toxicity. In this phase I study, we show that
myeloablative chemotherapy with sequential FluBu can be
combined with TMI at a dose of 3 Gy, 6 Gy, or 9 Gy. Although
this study was not designed to measure efﬁcacy, the median
survival of patients enrolled in the trial is an encouraging
result considering the overall poor prognosis in this group. It
could be argued that the use of TMI may allow extra-
medullary relapse, in part because of the presence of ma-
lignant cells harbored outside of the bone marrow. However,
patients who received TMI at 9 Gy in the bone marrow had,
on average, 50% of this dose delivered to other organs
(Figure 2). Therefore, we assume that the antitumor effect on
extramedullary sites of regimens including TMI 9 Gy or TBI
4 Gy are comparable, with the advantage of a more potent
antitumor effect on the bone marrow without an increase in
toxicity using the TMI 9 Gy dosing. In fact, the major extra-
hematologic toxicity recorded in this study was oralmucositis, with all patients experiencing Bearman grade 1 or
2mucositis. Time to engraftment was an important endpoint
of the study, based on the concern that the combination of
myeloablative chemotherapy with TMI could damage the
bone marrow microenvironment [43], preventing the
engraftment of donor stem cells. We observed, instead, that
there was rapid engraftment at each of the 4 tested radiation
doses, which is comparable to prior experience with this
conditioning regimen [30]. Furthermore, despite the addi-
tional immune suppression delivered by this augmented
conditioning, we could not detect any impairment of im-
mune reconstitution, with levels of lymphocyte subsets
comparable to those seen after other myeloablative condi-
tioning regimens [44]. Finally, it should be noted that ﬂu-
darabine and busulfan were delivered sequentially and not
concurrently, as has been previously reported [34,45]. This
may have contributed to the tolerability of the regimen,
although it may also compromise efﬁcacy.
Previous experiences with TMI-based conditioning uti-
lized a tomotherapy-based platform and were reported in
autologous [21] as well as allogeneic transplantations. In this
latter setting, TMI was added to a reduced-intensity condi-
tioning regimen [20]. Our current study demonstrates that
TMI can also be combinedwithmyeloablative chemotherapy.
In addition, our study represents the ﬁrst demonstration of
TMI delivery using a linear accelerator platform.
P. Patel et al. / Biol Blood Marrow Transplant 20 (2014) 2034e20412040Our results provide the rationale for the implementation
of a phase II trial using 9 Gy TMI in combination with
sequential FluBu in patients at high risk of relapse. Moreover,
new regimens with TMI and low-dose chemotherapy could
also be designed as myeloablative, nontoxic regimens and
could potentially be applied to patients with comorbidities
or to elderly patients, with the goal of ameliorating the high
relapse risk associated with reduced-intensity conditioning
without increasing the TRM.ACKNOWLEDGMENTS
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